Shopping Cart

Your shopping cart is currently empty

GSK_WRN4

Name: GSK_WRN4
Brand: TargetMol
SKU: T200332
Price: 953 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T200332Cas No. 2923008-66-4

GSK_WRN4 is a WRN helicase inhibitor with anticancer activity. It induces DNA double-strand breaks and inhibits MSI tumor cell growth, making it useful in cancer research.

GSK_WRN4

Copy Product Info

😃Good

Purity: 99.95%

Catalog No. T200332Cas No. 2923008-66-4

GSK_WRN4 is a WRN helicase inhibitor with anticancer activity. It induces DNA double-strand breaks and inhibits MSI tumor cell growth, making it useful in cancer research.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$953	-	In Stock
5 mg	$1,780	-	In Stock
10 mg	$2,380	-	In Stock
25 mg	$3,570	-	In Stock
50 mg	$4,790	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.95%

Appearance:Solid

Color:White

Resource Download

COA HNMR HPLC

Product Introduction

Bioactivity

Description	GSK_WRN4 is a WRN helicase inhibitor with anticancer activity. It induces DNA double-strand breaks and inhibits MSI tumor cell growth, making it useful in cancer research.
Targets&IC50	WRN helicase:7.6 (pIC50)
In vitro	GSK_WRN4 significantly inhibited WRN helicase activity with pIC50 value of 7.6. GSK_WRN4 (0.1-20 μM, 1.5-144h) treated SW48 cells in a time - and dose-dependent manner. [1]
In vivo	In a xenografted mouse model of colorectal cancer cell lines, dose-dependent tumor growth inhibition was observed by oral administration of GSK_WRN4 (30, 100, 300 mpk), and tumor growth was completely inhibited at the highest dose supported by favorable pharmacokinetics. Morphological and pathological analysis of explants showed that GSK_WRN4 treatment resulted in a decrease in SW48 tumor cell density, accompanied by increased stromal and extracellular matrix deposition. [1]

Chemical Properties

Molecular Weight	336.41
Formula	C₁₆H₂₀N₂O₄S
Cas No.	2923008-66-4
Smiles	O=C1NC(=CC=C1C(N[C@@H]2C=CS(=O)(=O)C2)=O)C3CCCCC3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (237.81 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (9.81 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.9726 mL	14.8628 mL	29.7256 mL	148.6282 mL
5 mM	0.5945 mL	2.9726 mL	5.9451 mL	29.7256 mL
10 mM	0.2973 mL	1.4863 mL	2.9726 mL	14.8628 mL
20 mM	0.1486 mL	0.7431 mL	1.4863 mL	7.4314 mL
50 mM	0.0595 mL	0.2973 mL	0.5945 mL	2.9726 mL
100 mM	0.0297 mL	0.1486 mL	0.2973 mL	1.4863 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc